![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Know Labs Inc | AMEX:KNW | AMEX | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.0095 | 2.55% | 0.3815 | 0.4084 | 0.3815 | 0.40 | 72,459 | 16:01:00 |
Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the third quarter ended June 30, 2023.
Financial Highlights:
Income Statement:
Three Months Ended, Nine Months Ended, June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022 REVENUE- DIGITAL ASSET SALES $-
$
-
$
-
$
4,360,087
OPERATING EXPENSES- RESEARCH AND DEVELOPMENT EXPENSES
1,879,519
1,272,537
6,186,039
3,406,996
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES
1,359,782
1,588,823
5,507,511
4,253,997
SELLING AND TRANSACTIONAL COSTS FOR DIGITAL ASSETS
-
164,093
-
3,436,955
Total operating expenses
3,239,301
3,025,453
11,693,550
11,097,948
OPERATING LOSS
(3,239,301
)
(3,025,453
)
(11,693,550
)
(6,737,861
)
OTHER (EXPENSE): Interest income (expense), net23,511
(239,760
)
(275,301
)
(8,024,709
)
Other (expense) income(384,137
)
261,927
(384,137
)
261,927
Total other (expense), net
(360,626
)
22,167
(659,438
)
(7,762,782
)
LOSS BEFORE INCOME TAXES(3,599,927
)
(3,003,286
)
(12,352,988
)
(14,500,643
)
Income tax expense-
-
-
-
NET LOSS
(3,599,927
)
(3,003,286
)
(12,352,988
)
(14,500,643
)
Common stock dividends on Series D Preferred Stock(1,627,230
)
-
(1,627,230
)
-
Deemed dividends on Series C and D Preferred Stock
(3,337,494
)
-
(3,337,494
)
-
NET LOSS AVAILABLE TO COMMON SHAREHOLDERS $
(8,564,651
)
$(3,003,286
)
$(17,317,712
)
$(14,500,643
)
Basic and diluted loss per share $(0.18
)
$(0.07
)
$(0.36
)
$(0.37
)
Weighted average shares of common stock outstanding- basic and diluted48,928,911
43,760,904
48,604,274
39,032,860
Balance Sheet:
June 30, 2023 September 30, 2022 (1) ASSETS Unaudited CURRENT ASSETS: Cash and cash equivalents $3,928,865
$
12,593,692
Total current assets
3,928,865
12,593,692
PROPERTY AND EQUIPMENT, NET
300,097
862,977
OTHER ASSETS Other assets
15,766
13,767
Operating lease right of use asset
191,769
287,930
TOTAL ASSETS $
4,436,497
$
13,758,366
LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable - trade $
526,688
$
526,968
Accrued expenses
416,191
462,940
Accrued expenses - related parties
320,427
348,264
Convertible notes payable, net
2,255,066
2,255,066
Current portion of operating lease right of use liability
202,712
215,397
Total current liabilities
3,721,084
3,808,635
NON-CURRENT LIABILITIES: Operating lease right of use liability, net of current portion
-
87,118
Total non-current liabilities
-
87,118
COMMITMENTS AND CONTINGENCIES (Note 12)
-
-
STOCKHOLDERS' EQUITY Preferred stock - $0.001 par value, 5,000,000 shares authorized, Series C and D shares issued and outstanding as follows: Series C Convertible Preferred stock $0.001 par value, 1,785,715 shares authorized, 1,785,715 shares issued and outstanding at 6/30/2023 and 9/30/2022, respectively
1,790
1,790
Series D Convertible Preferred stock $0.001 par value, 1,016,014 shares authorized, 1,016,004 shares issued and outstanding at 6/30/2023 and 9/30/2022, respectively
1,015
1,015
Common stock - $0.001 par value, 200,000,000 shares authorized, 52,358,463 and 48,156,062 shares issued and outstanding at 6/30/2023 and 9/30/2022, respectively
52,358
48,158
Additional paid in capital
119,375,700
111,209,388
Accumulated deficit
(118,715,450
)
(101,397,738
)
Total stockholders' equity715,413
9,862,613
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $
4,436,497
$
13,758,366
(1) Derived from audited consolidated balance sheet.
-
-
Cash Flow:
Nine Months Ended, June 30, 2023 June 30, 2022 CASH FLOWS FROM OPERATING ACTIVITIES: Net loss $(12,352,988
)
$(14,500,643
)
Adjustments to reconcile net loss to net cash (used in) operating activities Depreciation and amortization259,541
218,683
Issuance of common stock for services
-
153,000
Issuance of common stock warrants for services
-
71,220
Loss on disposal of assets
384,137
-
Modification of notes and warrants - interest expense
349,721
244,260
Stock based compensation- stock option grants
2,464,045
1,555,875
Right of use, net
(3,642
)
(20,705
)
Gain on forgiveness of notes payable-PPP Loans-
(252,700
)
Amortization of debt discount to interest expense-
7,272,911
Changes in operating assets and liabilities: Other long-term assets
(1,999
)
-
Accounts receivable-related party
-
(46,146
)
Accounts payable - trade and accrued expenses(74,866
)
1,612,959
NET CASH (USED IN) OPERATING ACTIVITIES
(8,976,051
)
(3,691,286
)
CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of property and equipment(80,798
)
(843,557
)
NET CASH (USED IN) INVESTING ACTIVITIES:(80,798
)
(843,557
)
CASH FLOWS FROM FINANCING ACTIVITIES: Settlement of notes payable-PPP loans-
(179,103
)
Proceeds from issuance of common stock for stock options exercise4,687
13,687
Proceeds from issuance of common stock for warrant exercise
387,335
793,986
NET CASH PROVIDED BY FINANCING ACTIVITIES
392,022
628,570
NET (DECREASE) IN CASH AND CASH EQUIVALENTS
(8,664,827
)
(3,906,273
)
CASH AND CASH EQUIVALENTS, beginning of period12,593,692
12,258,218
CASH AND CASH EQUIVALENTS, end of period $
3,928,865
$
8,351,945
Conference Call:
Know Labs will host an audio webcast to discuss its results and provide a business update today, August 14, 2023, at 4:30 pm ET (1:30 pm PT). The live webcast will be available on the Investors page of the Company’s website, www.knowlabs.co/investors, and a replay will be available for six months.
Participant Dial-In: 877-514-3621 / +1 215-268-9856
Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=QDtTlLZk
A copy of the form 10-Q filed with the SEC can also be downloaded from the Company’s website.
About Know Labs, Inc.
Know Labs, Inc. is a public company whose shares trade on the NYSE American Exchange under the stock symbol “KNW.” The Company’s technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The Company refers to its technology as Bio-RFID™. The Bio-RFID technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of our Bio-RFID technology will be in a product marketed as a non-invasive glucose monitor. The device will provide the user with accessible and affordable real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration clearance prior to its introduction to the market.
Safe Harbor Statement
This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2022, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230814286015/en/
For Know Labs Media Inquiries Contact: Matter Health Laura Bastardi Knowlabs@matternow.com Ph. (603) 494-6667 Know Labs, Inc. Contact: Jordyn Hujar jordyn@knowlabs.co Ph. (206) 629-6414
1 Year Know Labs Chart |
1 Month Know Labs Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions